Journal of Clinical Oncology
Articles in this Issue
Randomized trial of urinary tumor DNA (utDNA) testing-guided cystoscopy in high-risk/very high-risk non-muscle-invasive bladder cancer (NMIBC): TRUCE-LB02.
TPS911 Background: Patients with high-risk or very high-risk non–muscle-invasive bladder cancer (NMIBC) require intensive...
Genomic characterization of upper tract urothelial carcinoma (UTUC) with or without sarcomatoid differentiation.
862 Background: Sarcomatoid variant of UTUC (S-UTUC) is a rare and aggressive malignancy. Due to the paucity of reported l...
Impact of GLP1 receptor agonists on severity of prostate cancer at diagnosis: A propensity score weighted analysis.
352 Background: Glucagon-like peptide 1 (GLP1) receptor expression in prostate cancer tissue has raised concerns that GLP1...
A phase II study evaluating the efficacy and safety of perioperative enfortumab vedotin plus toripalimab combined with endoscope-based kidney-sparing surgery for patients with high-risk upper tract urothelial carcinoma (WUTSUP-04-EV-JS001).
TPS905 Background: Radical nephroureterectomy (RNU) for high-risk upper tract urothelial carcinoma (UTUC) often compromise...
Prognostic significance of depressive symptoms in men with advance prostate cancer (PC): Results from the IRONMAN registry.
139 Background: Depression is common in advanced PC and impacts quality of life. Whether depressive symptoms directly infl...
Early-onset prostate cancer: A time series analysis of age-stratified trends.
354 Background: Prostate cancer (PC) epidemiology has undergone substantial transformation over the past three decades, in...
Prevalence and clinical impact of actionable genomic alterations in non–clear cell renal cell carcinoma: A review of NGS-based trials and real-world data.
556 Background: Non–clear cell renal cell carcinoma (nccRCC) comprises biologically diverse subtypes with limited evidence...
Safety profile of darolutamide + ADT compared to enzalutamide, apalutamide, and abiraterone in metastatic castration-sensitive prostate cancer: Results from the first safety matching-adjusted indirect comparison.
137 Background: Indirect treatment comparisons in metastatic castration-sensitive prostate cancer (mCSPC) have predominant...
Prospective evaluation of sexual function over 5 years in patients with localized prostate cancer treated with carbon-ion radiotherapy.
355 Background: Curative treatment options for localized prostate cancer (PC) include surgery and radiation therapy; howev...
Blood and urine liquid biopsy for molecular monitoring in HER2-positive muscle-invasive bladder cancer under bladder-preserving therapy.
847 Background: While trimodal therapy is the current standard for organ preservation in muscle-invasive bladder cancer (M...
ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following prior therapies for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).
770 Background: Erdafitinib (E), a pan-FGFR inhibitor, is approved for FGFR3-altered mUC after prior therapy. Enfortumab V...
Characterization of HER2 expression in prostate cancer compared with other solid tumors.
255 Background: Recent reports of promising responses to the human epidermal growth factor receptor 2 (HER2)-targeting ant...
Comprehensive multi-layered omics analysis of the UBC landscape for precision medicine and its clinical implications: From deciphering distinct molecular heterogeneity to guiding treatment decision-making and developing tailored therapeutic strategies.
840 Background: Conventional transcriptomic subtyping of non-muscle invasive (NMIBC) and muscle-invasive bladder cancer (M...
Aggressive-variant prostate cancer features and therapeutic outcomes in patients with de-novo metastatic hormone-sensitive prostate cancer.
264 Background: Aggressive variant prostate cancer (AVPC) was considered a combination of aggressive phenotypes in metasta...
Outcomes of cabazitaxel following 177Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).
84 Background: LuPSMA and cabazitaxel are both standard of care options for men with PSMA-positive mCRPC post docetaxel. T...
Identifying and predicting non-cancer mortality risk in mHSPC following doublet therapy in the STAMPEDE trial.
134 Background: Body composition features derived from baseline computed tomography (CT) imaging can reveal clinical pheno...
The impact of the 2025 NCCN update in defining very high-risk prostate cancer on surgical outcomes after robot-assisted radical prostatectomy: A retrospective cohort analysis.
340 Background: Under the pre-2025 National Comprehensive Cancer Network (NCCN) definition, very high-risk (VHR) prostate...
First results from CORE-008 cohort A: Phase 2 study of intravesical cretostimogene grenadenorepvec in patients with high-risk BCG-naïve non-muscle invasive bladder cancer.
756 Background: Standard of care treatment for HR NIMBC includes TURBT followed by intravesical BCG. However, high recurre...
Real-world comparison of prostate-specific antigen (PSA) response in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with apalutamide (APA) without docetaxel vs darolutamide (DARO) without docetaxel.
106 Background: APA and DARO are androgen receptor pathway inhibitors (ARPIs) approved for the treatment of mCSPC in combi...
Clinical characteristics and molecular evolution of treatment-emergent small-cell/neuroendocrine prostate cancer in the era of doublet and triplet systemic therapy.
240 Background: Transformation to treatment-emergent small-cell/neuroendocrine prostate cancer (teSC/NEPC) represents one...
Real-world treatment outcomes of advanced prostate cancer among Black compared to White men in the Medstar Health Network.
97 Background: Health disparities in prostate cancer (PC) have been well-documented, with Black men historically experienc...
Evaluation of the safety and efficacy of daily oral <i>Angelica gigas</i> Nakai (AGN)-INM176 in prostate cancer patients with rising plasma PSA (phase I/II trial).
TPS413 Background: There are currently no FDA approved modalities for intercepting biochemically recurrent prostate cancer...
Clinical outcomes among patients with metastatic hormone-sensitive prostate cancer in contemporary real-world US clinical practice: A prostate cancer disease observation (PRECISION) data platform analysis.
77 Background: The incidence of metastatic hormone-sensitive prostate cancer (mHSPC) is increasing in the US, likely due t...
Transcriptomic characterization of prostate cancer in patients with HIV infection.
396 Background: Prostate cancer is the most commonly diagnosed malignancy in the aging population of men living with HIV....
Phase 3 study of <sup>68</sup> Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer (BIPASS).
TPS406 Background: Prostate cancer (PC) is diagnosed through directed & template/anatomical biopsy based on clinical a...